

WYOMING DEPARTMENT OF HEALTH AIDS DRUG ASSISTANCE PROGRAM OPEN FORMULARY AND PRESCRIBING GUIDELINES

Effective March 2019
This formulary supersedes all previous editions.

Drugs provided by the Wyoming AIDS Drug Assistance Program (ADAP) must not exceed \$50,000 per year / \$5,000 per month / \$3400 per claim per client. Claims beyond that cap must be pre-authorized. Except for the following drug and class exclusions, this is an open formulary for all eligible enrollees.

Specific Exclusions Examples

Hemophilia medications

Botulinum toxin Botox, Myobloc

Gonadotropin

Finasteride (except for prostate disorders)

Hyaluronic acid derivatives Hyalgan, Synvisc

Immune globulin intravenous (IGIV)

Sandoglobulin, Venoglobulin

Injectable muscle relaxants

Lioresal

Mifepristone Minoxidil

Antirheumatic injectables Enbrel

Monoclonal antibodies Remicade, Synagis

Nutritional supplements Ensure

Propoxyphene

Recombinant human growth hormone (HGH) Geref, Humatrope

Synthetic growth hormone Egrifta

Class Exclusions Examples

Durable medical equipment Cosmetic medications

Erectile dysfunction pharmaceuticals Viagra, Levitra, Cialis, Caverject

Female sexual dysfunction pharmaceuticals Addyi

Fertility drugs Herbal medications

Nicotine cessation products

Other Special Provisions

- Vitamins and pain relievers (i.e. ibuprofen) are covered when prescribed by a physician.
- · Opioid limits: 120 MME plus 4-6 SA tabs per day.
- · Hepatitis C treatment medications (i.e. Harvoni, Viekira XR, Sovaldi, Ribavirin, Zepatier, Technivie, Daklinza, Epclusa) must be prior authorized. To be eligible, clients must have applied for prior authorization from their insurance plan and the WY ADAP Hepatitis C Treatment checklist must be completed and signed by the provider and client.
- Enrollees with health insurance must use that insurance as the primary payer; the Wyoming ADAP program will become the secondary payer.



WYOMING DEPARTMENT OF HEALTH AIDS DRUG ASSISTANCE PROGRAM OPEN FORMULARY AND PRESCRIBING GUIDELINES

Effective March 2019
This formulary supersedes all previous editions.